Document is current
Any future updates will be listed below
-
Authors
Hanboonkunupakarn, Borimas
Mukaka, Mavuto
Jittamala, Podjanee
Poovorawan, Kittiyod
Pongsuwan, Pongphaya
Stockdale, Lisa
Provstgaard-Morys, Samuel
Chotivanich, Kesinee
Tarning, Joel
Hoglund, Richard M.
Chimjinda, Natenapa
Ewer, Katie http://orcid.org/0000-0001-9827-9836
Ramos-Lopez, Fernando http://orcid.org/0000-0002-9997-7879
Day, Nicholas P. J. http://orcid.org/0000-0003-2309-1171
Dondorp, Arjen M. http://orcid.org/0000-0001-5190-2395
Hill, Adrian V. http://orcid.org/0000-0003-0900-9629
White, Nicholas J.
von Seidlein, Lorenz http://orcid.org/0000-0002-0282-6469
Pukrittayakamee, Sasithon
- License Information
-
More Information
Article History
Received: 20 February 2024
Accepted: 27 June 2024
First Online: 6 July 2024
Competing interests
: A.V.H. and K.J.E. are named as coinventors on patent applications related to R21. Katie J Ewer was an employee of the University of Oxford at the time of the work and is now an employee of GSK. KJE owns restricted shares in GSK. No competing interests were disclosed for other authors.
: The protocol was approved by the Mahidol Faculty Tropical Medicine (TMEC 22-034) and Oxford University’s ethics review board (OxTREC ref 09–22). The trial was undertaken in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines and good clinical practice (ICH GCP). Written informed consent was obtained from each participant before study procedures were initiated (Clinical Trials.gov identifier: NCT05252845).
